As of December 31, 2025 and March 31, 2025, the most significant of these were the Company's investments in Arbutus and Datavant, which are accounted for using the fair value option.
all, which could negatively affect our capacity for certain strategic transactions or our ability to make other important investments. In addition, high levels of inflation and interest rate fluctuat…
Reciprocal relationship from OGN graph: Reciprocal relationship from ROIV graph: all, which could negatively affect our capacity for certain strategic transactions or our ability to make other import…
In April 2024, pursuant to this share repurchase program, we entered into a share repurchase agreement with Sumitomo Pharma Co., Ltd. ("Sumitomo") and repurchased all 71,251,083 common shares held by S
Reciprocal relationship from IMVT graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT g…
of any renegotiated trade agreements, nor can we determine the impact they may have on our business. Any such changes could have a material adverse effect on our business, financial condition and res…
Reciprocal relationship from OGN graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from OGN graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from OGN grap…
Roivant Sciences Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
ROIV-DEBT-12255
Warrants outstanding: 0.01
90%
xbrl warrant detail from xbrl 2025-03-31.
ROIV-DEBT
Debt stack $108.9M
90%
Market cache reports total debt of $108.9M.
Roivant Sciences Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Roivant Sciences Ltd..
Roivant Sciences Ltd. Ownership
Holder
Name
Confidence
Evidence
ROIV-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 443 tracked holders.